Catálogo de publicaciones - libros

Palabras clave – provistas por la editorial

Breast cancer treatment; Photodynamic therapy; Inorganic nanoparticles; Active targeting; cathepsins; BAX; MOMP; ubiquitination; apoptosis; chemotherapy; cancer; nanoerythrosome; nanoerythrocyte; nanovesicles; biomimetic; cancer therapy; diagnostics; imaging agents; cell cycle; cyclin-dependent kinase; p16; p21; p27; breast cancer; prognosis; drug delivery; HL60; leukemia; prodrug; resistance; retinoic acid; vitamin K; drug repurposing; COVID-19; pandemic; vaccination; multi-drug resistance; enhanced permeation and retention effect; nanotherapeutics; cancer theranostic; clinical translation; cell-penetrating peptides; protein transduction domains; tumor imaging; targeted therapies; dog; comparative oncology; molecular targets; spheroids; tumoroids; hydrogel; collagen; agarose; mammary spheroids; tissue engineering; cisplatin; melanoma; melanin nanoparticles; cytotoxicity; laser medical applications; hyperthermia; antimitotics; mitotic slippage; spindle assembly checkpoint; clinical trials; TRAIL; cancer stem cells; TRAIL resistance; angiogenesis; on-demand drug delivery systems; electrospun nanofibers; poly (N-isopropylacrylamide); gold nanorods; paclitaxel; β-Cyclodextrin; SPIONs; metallodrugs; RAPTA derivatives; phosphino-amine ligands; CTCs; NSCLCs; metastasis suppression; curcumin; flavonoids; TNBC; immunotherapy; immune checkpoint; nanocarrier; combinational immunotherapy; lung cancer; miRNA; oncomiRs; photodynamic therapy PDT; porphyrin; iron oxide nanoparticles; mesoporous silica nanoparticles; antibody functionalization; targeted drug delivery systems; molecular-targeted therapies; multifunctional enzymes; HCC; CHRNA5; metastasis; stemness property; sorafenib sensitivity; neoantigens; vaccine; Patched; chemotherapy resistance; metastases; persistent cells; adrenocortical carcinoma; BUB3; mitosis; senescence; anticancer target; boron neutron capture therapy; 4-borono-l-phenylalanine; drug discovery; solubility; mebendazole; polymer; HPMA; controlled drug release; PLK1; BI2536; Navitoclax; slippage; PD-1; gemcitabine; new anti-cancer drugs; precision medicine; undruggable targets; non-coding RNAs; oligonucleotide therapeutics; n/a